Kerri Fitzgerald

Cancer Nursing Today nonprod

The effect of bone marrow (BM) blasts on the outcome of patients with myelofibrosis (MF) is poorly understood, except for in those with ?10% BM blasts, which represents a more aggressive accelerated phase. A study published in Clinical Lymphoma, Myeloma &amp; Leukemia found that patients with MF with ?5% BM blasts are a high-risk group with adverse clinical characteristics and inferior outcomes. However, these patients had improved survival with treatment with ruxolitinib, according to the study.Researchers assessed 1,412 patients with MF who were stratified by BM blasts and therapy.Among the cohort, 7% had 5% to 9% BM blasts, while 4% had ?10% BM blasts. A total of 44% of patients were treated with ruxolitinib during their disease course.Median overall survival (OS) was 64 months among patients with 0% to 1% BM blasts, 48 months among patients with 2% to 4% BM blasts, and 22 months among patients with 5% to 9% BM blasts (P&lt;0.001).Patients with 5% to 9% BM blasts had similar OS compared with patients with ?10% BM blasts (22 months vs. 14 months; P=0.73). All patients with &lt;10% blasts who were treated with ruxolitinib had superior OS than those who did not receive ruxolitinib.

Is Ruxolitinib Beneficial for Patients with Myelofibrosis with ?5% Bone Marrow Blasts?

Myelofibrosis

The effect of bone marrow (BM) blasts on the outcome of patients with myelofibrosis (MF) is poorly understood, except for in those with ?10% BM blasts, which represents a more aggressive accelerated phase. A study published in Clinical Lymphoma, Myeloma &amp; Leukemia found that patients with MF with ?5% BM blasts are a high-risk group [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe